[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vaccines from age 5?", "description": "Pfizer for 5 to 11 year olds\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results\n\n5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responses\n\nCompanies plan to submit these data to the FDA, EMA and other regulatory agencies\n\nResults in children under 5 years of age are expected as soon as later this year\n\nN = 4,500, Finland, Poland, Spain, US\n\nTwo dose, 21 days apart\n\n10 ug, not 30 ug\n\nSimilar results to 30 ug in 15 to 25 year olds\n\nPhase 2/3 trial\n\nSide effects reported with the vaccine include:\n\nA severe allergic reaction would usually occur within a few minutes to one hour\n\nDifficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness\n\nMyocarditis and pericarditis have occurred in some people who have received the vaccine.\n\nIn most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. \n\nThe chance of having this occur is very low. \n\nchest pain\n\nshortness of breath\n\nfeelings of having a fast-beating, fluttering, or pounding heart\n\nOther side effects\n\ninjection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); diarrhea; vomiting; arm pain\nThere is no information on the use of the vaccine with other vaccines\n\nFDA tweet about ivermectin\n\nhttps://twitter.com/US_FDA/status/1429050070243192839?s=20\n\nhttps://twitter.com/US_FDA\n\nInfectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection \n\nhttps://sph.umd.edu/news/covid-19-virus-evolving-get-better-becoming-airborne-new-study-shows\n\nhttps://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab797/6370149\n\nEpidemiology implicates airborne transmission, aerosol infectiousness \n\nMethods\n\nConfirmed cases gave:\n\nBlood, saliva, mid-turbinate and fomite (phone) swabs\n\n30-minute breath samples while vocalizing\nwith and without masks\n\nUp to two visits two days apart\n\nQuantified and sequenced viral RNA, cultured virus\n\nResults\n\nN = 49 seronegative cases\n\nMean days post onset 3.8 \u00b1 2.1\n\nMay 2020 through April 2021\n\nDetected SARS-CoV-2 RNA in alpha variant\n\n45% of fine (less than 5 \u03bcm) aerosols\n\n31% of coarse ( more than 5 \u03bcm) aerosols\n\n65% of fomite samples\n\nMasks reduced viral RNA by:\n\n48% in fine aerosols\n\n77% in coarse aerosols\n\nCloth and surgical masks were not significantly different\n\nThe alpha variant (compared with earlier viruses)\n\n43-fold increase in fine aerosol viral RNA\n\nRemained a significant 18-fold increase adjusting for viral RNA in saliva, swabs, and other potential confounders\n\nConclusion\n\nSARS-CoV-2 is evolving toward more efficient aerosol generation\n\nLoose-fitting masks provide significant but only modest source control\n\nContinued layered controls and tight-fitting masks and respirators will be necessary", "link": "https://www.youtube.com/watch?v=IsGLNNewJlU", "date_published": "2021-09-21 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]